Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II placebo-controlled repeat-dose study of CG100649 in male subjects with primary osteoarthritis
2007-001197-93Phase 2Completed
- Sponsor
- Crystal Genomics
- Start
- Jun 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of polmacoxib in osteoarthritis (OA), hip osteoarthritis and knee osteoarthritis (OA) (4 arms), sponsored by Crystal Genomics. Primary endpoint: Change in WOMAC OA index sum score at Day 21 versus baseline. Started Jun 2007; status: completed.
02
Drugs
polmacoxib
03
Conditions
osteoarthritis (OA)hip osteoarthritisknee osteoarthritis (OA)
Beyond the preview
Go deeper on 2007-001197-93.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001197-93.